Mobilan - Panacela Labs

Drug Profile

Mobilan - Panacela Labs

Alternative Names: M-VM3; MVAME03; Prostate cancer vaccine - Pancela/Cleveland BioLabs

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Childrens Cancer Institute Australia for Medical Research; Cleveland BioLabs; Cleveland Clinic; Roswell Park Cancer Institute
  • Developer Panacela Labs
  • Class Antineoplastics; Cancer vaccines
  • Mechanism of Action Toll-like receptor 5 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 01 Sep 2017 Panacela completes a phase I trial in Prostate cancer in Russia (Intratumoural) (NCT02654938)
  • 01 Jul 2016 Phase-I/II clinical trials in Prostate cancer (Neoadjuvant therapy, Newly diagnosed) in Russia (Intratumoural) (NCT02844699)
  • 01 Jan 2015 The US FDA approves IND application for mobilan in Prostate cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top